Randomized Study Comparing Endeavor With Cypher Stents (PROTECT) (PROTECT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00476957 |
Recruitment Status :
Completed
First Posted : May 22, 2007
Results First Posted : March 17, 2014
Last Update Posted : November 10, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
The PROTECT TRIAL is a randomized stent trial with 8800 patients in approximately 200 hospitals, which is designed to evaluate whether the Endeavor stent PROTECTS against late stent thrombosis resulting in less deaths and myocardial infarctions.
Study Stents:
Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System or next generation model Cordis Cypher® Sirolimus-eluting Coronary Stent, Cordis Cypher Select® Sirolimus-eluting Coronary Stent or next generation model
Primary Objective: To compare overall stent thrombosis rate of the Endeavor® Zotarolimus Eluting Coronary Stent System versus the Cypher® Sirolimus-eluting Coronary Stent in a patient population requiring stent implantation
Secondary Objective: To compare the composite endpoint of total death or cardiac death combined with the number of patients with all non-fatal myocardial infarctions as well as the number of patients with large non-fatal myocardial infarctions for Endeavor® Zotarolimus Eluting Coronary Stent System versus the Cypher® Sirolimus-eluting Coronary Stent in a patient population requiring stent implantation.
To assess the safety and efficacy in patient subgroups with specific demographics, clinical indications and/or vessel- or lesion characteristics.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ischemic Heart Disease | Device: Stent | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 8709 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Health Services Research |
Official Title: | PROTECT Trial: Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial |
Study Start Date : | June 2007 |
Actual Primary Completion Date : | May 2012 |
Actual Study Completion Date : | July 2014 |
Arm | Intervention/treatment |
---|---|
Active Comparator: 1
Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System
|
Device: Stent
Stent implantation
Other Name: Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System |
Active Comparator: 2
Cordis Cypher® Sirolimus-eluting Coronary Stent
|
Device: Stent
Stent implantation
Other Name: Cordis Cypher® Sirolimus-eluting Coronary Stent |
- To Compare Overall Definite or Probable Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System Versus the Cypher® Sirolimus-eluting Coronary Stent in a Patient Population Requiring Stent Implantation [ Time Frame: 3 years ]Definite or probable stent thrombosis rate.
- Composites of (Cardiac) Death and (Large) Non-fatal Myocardial Infarctions [ Time Frame: 3 years ]Total death and large non-fatal myocardial infarctions Total death and non-fatal myocardial infarctions Cardiac death and large non-fatal MI Cardiac death and non-fatal myocardial infarctions

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient is > 18 years of age (or minimum age as required by local regulations).
- The patient has consented to participate and has authorized the collection and release of his medical information by signing the "Patient Informed Consent Form".
- All lesions requiring interventions (target lesions - one to a maximum of four) in one or more native coronary arteries are amendable for implantation of one or more Endeavor® Zotarolimus Eluting Coronary Stent System or Cypher® Sirolimus-eluting Coronary Stent*.
- Patient indication, lesion length and vessel diameter of the target lesion(s) are according to the 'Indications for Use' as mentioned in the 'Instructions for Use' that comes with every Endeavor® Zotarolimus Eluting Coronary Stent System and Cypher® Sirolimus-eluting Coronary Stent. Patients should qualify for both systems before randomization*.
- The patient is willing and able to cooperate with study procedures and required follow up visits.
Exclusion Criteria:
- Women with known pregnancy or who are lactating.
- Planned elective surgery necessitating discontinuation of clopidogrel within the regular planned period of clopidogrel administration.
- Patients expected not to be compliant with the anti-platelet and/or anticoagulation therapy regimen.
- Previous brachy-therapy.
- Previous implantation of a drug eluting stent.
- Previous implantation of a bare metal stent in the preceding year.
- Simultaneous or planned intervention other non cardiac vessels including but not limited to renal artery or carotid artery.
- Current medical condition with a life expectancy of less than 3 years.
- Manifest acute severe heart failure (Killip class III-IV).
- The patient is currently, and during the first 3 years of the PROTECT trial, participating in another investigational device or drug study that clinically interferes with the PROTECT-study endpoints; or requires coronary angiography or other coronary artery imaging procedures. The patient may only be enrolled in the PROTECT-study once.
- Patients with medical conditions that preclude the follow-up as defined in the protocol or that otherwise limits participation in this study.
- Patients on warfarin or similar anti-coagulant therapy.
- Patients with hypersensitivity or allergies to one of the drugs or components indicated in the Instructions for Use of either stents.
- Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon.
- Patients in whom anti-platelet and/or anticoagulation therapy is contraindicated.
- Transplant patients.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00476957
Netherlands | |
196 enrolling sites Worldwide | |
Maastricht, Netherlands |
Principal Investigator: | Edoardo Camenzind, MD | University of Geneva, Switzerland | |
Principal Investigator: | Laura Mauri, MD | Brigham and Women's Hospital, US | |
Principal Investigator: | William O'Neill, MD | University of Miami Miller School of Medicine, US | |
Principal Investigator: | Prof. Patrick W. Serruys, MD, PhD | Erasmus MC, Rotterdam, the Netherlands | |
Principal Investigator: | Prof. Philippe Gabriel Steg, MD, PhD | Département de Cardiologie, Hôpital Bichat-Claude Bernard, Assistance Publique - Hôpitaux de Paris, France | |
Principal Investigator: | William Wijns, MD, PhD | O.L.V. Hospital, Aalst, Belgium |
Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Medtronic Vascular |
ClinicalTrials.gov Identifier: | NCT00476957 History of Changes |
Other Study ID Numbers: |
Version 1.0 - 12 April 2007 |
First Posted: | May 22, 2007 Key Record Dates |
Results First Posted: | March 17, 2014 |
Last Update Posted: | November 10, 2014 |
Last Verified: | November 2014 |
Keywords provided by Medtronic Vascular:
Drug Eluting Stents Interventional Cardiology |
Additional relevant MeSH terms:
Heart Diseases Myocardial Ischemia Coronary Artery Disease Cardiovascular Diseases Vascular Diseases Coronary Disease Arteriosclerosis Arterial Occlusive Diseases Sirolimus |
Anti-Bacterial Agents Anti-Infective Agents Antibiotics, Antineoplastic Antineoplastic Agents Antifungal Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |